Immunomedics, Inc. (NASDAQ:IMMU) marched up 234% compared to a 52-week low price of $5.00. The shares were last seen trading -1.07% lower, taking the closing price at $16.7 on 04/19/2018. At recent session, the prices were hovering between $16.375 and $17.69. This company shares are 21.74% off its target price of $20.33 and the current market capitalization stands at $2.88B. The recent change has given its price a 4.25% lead over SMA 50 and -11.78% deficit over its 52-week high. The stock witnessed 4.77% gains, 5.43% gains and 49.51% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found IMMU’s volatility during a week at 5.11% and during a month it has been found around 5.92%.Immunomedics, Inc. (IMMU) Top Holders
Institutional investors currently hold around $2.09 billion or 78.2% in IMMU stock. Look at its top three institutional owners. Venbio Select Advisor Llc owns $271.17 million in Immunomedics, Inc., which represents roughly 9.42% of the company’s market cap and approximately 13.01% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 9,064,259 shares of the stock are valued at $153.01 million. The third largest holder is Orbimed Advisors Llc, which currently holds $142.83 million worth of this stock and that ownership represents nearly 4.96% of its market capitalization.
At the end of 12/31/2017 reporting period, 94 institutional holders increased their position in Immunomedics, Inc. (NASDAQ:IMMU) by some 25,601,556 shares, 74 decreased positions by 16,406,315 and 17 held positions by 81,492,819. That puts total institutional holdings at 123,500,690 shares, according to SEC filings. The stock grabbed 34 new institutional investments totaling 6,957,941 shares while 27 institutional investors sold out their entire positions totaling 8,361,268 shares.Immunomedics, Inc. (NASDAQ:IMMU) Insider Trades
Multiple company employees have indulged in significant insider trading. Immunomedics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Goldenberg David M has sold 117,729 shares of Immunomedics, Inc. (IMMU) in trading session dated Mar. 07, 2018. These shares are worth $2,049,662 and were traded at $17.41 each. The SEC filing shows that Markison Brian A performed a sale of 8,390 shares. The Director disposed these shares by way of transaction on Nov. 20, 2017. The company’s shares were given away at $11.89 per share worth to an income of some $99,757 on account of Markison Brian A.
, Venbio Select Advisor Llc, purchased 1,325,000 common shares of Immunomedics, Inc. (IMMU) in the open market. In a transaction dated Nov. 15, 2017, the shares were bought at an average price of $10.47, giving away a sum of $13,872,750. After this purchase, 16,064,461 common shares of IMMU are directly owned by the insider, with total stake valued at $268,276,499.
In the transaction dated Nov. 15, 2017, the great number of shares acquired came courtesy the; Aghazadeh Behzad added a total of 1,325,000 shares at an average price of $10.47, amounting to approximately $13,872,750. The insider now directly owns 16,064,461 shares worth $268,276,499.Immunomedics, Inc. (IMMU) Analyst Guide
Several analysts have released their opinion on Immunomedics, Inc. (NASDAQ:IMMU), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.